Chel Hun Choi, MD, Samsung Medical Center, Seoul, South Korea, discusses the ongoing of the Phase I/IIa study (NCT04800978) investigating the combination of BVAC-C and durvalumab in HPV-positive recurrent cervical carcinoma. BVAC-C, a novel immunotherapeutic vaccine, showed favorable tolerability in phase I, prompting its combination with durvalumab, an anti-PD-L1 therapy, to enhance anti-tumor immune responses. Interim analysis revealed a promising 6-month progression-free survival rate of 51%, with notable objective response and disease control rates. Immune responses correlated with clinical outcomes, supporting the combination’s efficacy. Adverse events were mostly manageable, indicating a manageable safety profile. Further studies are needed to explore potential biomarkers of treatment response. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
